CTOs on the Move

Gyroscope Therapeutics

www.gyroscopetx.com

 
Gyroscope Therapeutics is a clinical-stage gene therapy company developing gene therapy beyond rare disease to treat diseases of the eye that cause vision loss and blindness. The company was acquired by Novartis, a leading global medicines company, in February 2022.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.gyroscopetx.com
  • 2200 Renaissance Boulevard Suite 410
    King of Prussia, PA USA 19406
  • Phone: 267.523.2100

Executives

Name Title Contact Details

Similar Companies

Omni Environmental Services

Omni Environmental Services is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Timtec

Timtec is a Newark, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allucent

Allucent is a global biopharmaceutical services company founded in 2022 through the merger of several specialized providers. The company focuses on supporting small and mid-sized biotech firms in developing innovative treatments for patients with unmet medical needs. With over 30 years of combined experience, Allucent offers a range of services including regulatory consulting, clinical operations management, biometrics, and clinical pharmacology, particularly emphasizing oncology. Headquartered in Cary, North Carolina, Allucent has a strong global presence with offices in North America, Europe, Central/Eastern Europe, and Asia/Middle East. The company has conducted more than 825 clinical trials across over 70 countries, showcasing its extensive operational expertise. Allucent is dedicated to helping clients navigate the complexities of drug development and regulatory approval, ultimately accelerating the delivery of breakthrough therapies to patients.

Aragen Biosciences

Aragen Biosciences is a Morgan Hill, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Frequency Therapeutics

Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the controlled activation of progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone.